logo
  

Alaunos Extends Cooperative Research And Development Agreement With NCI

Alaunos Therapeutics, Inc. (TCRT) announced the company has extended its Cooperative Research and Development Agreement with the National Cancer Institute, using the Sleeping Beauty technology through January 2025. The NCI will work to generate proof of concept utilizing the company's non-viral Sleeping Beauty technology for personalized TCR-T cell therapy. The T-cell receptors (TCRs) that react to the patient's tumor will be identified from the patient and used to generate a TCR-T cell therapy.

The company believes that the non-viral Sleeping Beauty technology could rapidly and cost effectively produce safe and potent TCR-T cell therapies without the complexity of gene editing or viral approaches.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing company Lyft announced its foray into the media and advertisement business with the launch of Lyft Media as part of its vision to build the world's largest transportation media network. Lyft Media has built a suite of new products to allow advertisers to engage with Lyft's growing audience throughout their transportation journeys. Sysco Corp. (SYY) Tuesday reported a more than a three-times surge in fourth-quarter earnings, supported by 17.5 percent growth in sales. The company projects fiscal 2023 adjusted earnings to grow. Earnings for the quarter spiked to $509.99 million from $151.09 million last year. On a per share basis,... Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22.
RELATED NEWS
Follow RTT